Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Droloxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 13/20 | 0.82 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 0.82 |
| ▸ | MAPT | P10636 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | TP53 | P04637 | 3/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.82 |
| ▸ | ESRRG | P62508 | 3/20 | 0.82 |
| ▸ | PGR | P06401 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.82 |
| ▸ | ESRRB | O95718 | 2/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.82 |
| ▸ | PLD2 | O14939 | 1/20 | 0.82 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.81 |
| ▸ | NPC1 | O15118 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Droloxifene SCHEMBL5030004 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL28151286 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL30534774 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL30728607 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL1151787 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL4843 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL9782633 | 0.99 | ESR1 (0.80) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL28095331 | 0.99 | ESR1 (0.80) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL750110 | 0.99 | ESR1 (0.80) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL28095329 | 0.99 | ESR1 (0.80) | ESR1ESR2MAPTMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 39272 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| WO-2026102563-A1 | DISUBSTITUTED PYRIMIDOPYRROLE ANALOG AND USE THEREOF | 深圳湾实验室坪山生物医药研发转化中心 | 2026-05-21 | — | — | WO | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| EP-4695235-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | Cyrus Therapeutics Inc. (KR) | 2026-02-18 | — | — | EP | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| EP-4676544-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODIES AGAINST HUMAN L1CAM AND USES THEREOF | LigaChem Biosciences Inc. (KR) | 2026-01-14 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | claimed |
| WO-1996002242-A1 | USE OF DROLOXIFENE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | PFIZER INC. (US) | 1996-02-01 | — | — | WO | claimed |
| WO-1995024187-A1 | PLASTER-SHAPED TRANSDERMAL SYSTEM WITH A TAMOXIFEN DERIVATIVE | HEXAL AG (DE) | 1995-09-14 | — | — | WO | claimed |
| US-5441986-A | Administring droloxifen | PFIZER INC. (US) | 1995-08-15 | — | — | US | claimed |
| WO-1995018786-A1 | METHOD FOR THE PRODUCTION OF E-1-[4'-(2-DIMETHYLAMINOETHOXY)-PHENYL]-1-(3'-HYDROXYPHENYL)-2-PHENYL-1-BUTENE | KLINGE PHARMA GMBH (DE) | 1995-07-13 | — | — | WO | claimed |
| WO-1994026105-A1 | A METHOD FOR CONTROLLING A PEST POPULATION | Orion-Yhtymä Oy (FI) | 1994-11-24 | — | — | WO | claimed |
| EP-0509317-B1 | Use of droloxifene in the treatment of bone diseases | KLINGE CO CHEM PHARM FAB (DE) | 1994-11-17 | — | — | EP | claimed |
| US-5254594-A | Administering droloxifene or its salt | KLINGE PHARMA GMBH (DE) | 1993-10-19 | — | — | US | claimed |
| EP-0509317-A2 | Use of droloxifene in the treatment of bone diseases | Klinge Pharma GmbH (DE) | 1992-10-21 | — | — | EP | claimed |
| EP-0401243-B1 | MEDICINAL PREPARATIONS CHARACTERIZED BY A COMBINATION OF CYTOSTATIC AGENTS, HORMONAL THERAPEUTIC AGENTS AND PHOSPHONE DERIVATIVES | Henkel Kommanditgesellschaft auf Aktien (DE) | 1992-09-02 | — | — | EP | claimed |
| US-5047431-A | TREATMENT OF HORMONE-DEPENDENT MAMMARY TUMORS; ANTIESTROGENS | KLINGE PHARMA GMBH & CO. (DE) | 1991-09-10 | — | — | US | claimed |